187 related articles for article (PubMed ID: 37397090)
1.
Xia P; Chen J; Sapkota Y; Scott EN; Liu Y; Hudson MM; Rassekh SR; Carleton BC; Ross CJD; Chow EJ; Cheng Z
JACC CardioOncol; 2023 Jun; 5(3):360-373. PubMed ID: 37397090
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin induces cardiomyocyte apoptosis and atrophy through cyclin-dependent kinase 2-mediated activation of forkhead box O1.
Xia P; Chen J; Liu Y; Fletcher M; Jensen BC; Cheng Z
J Biol Chem; 2020 Mar; 295(13):4265-4276. PubMed ID: 32075913
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cyclin-dependent kinase 2 protects against doxorubicin-induced cardiomyocyte apoptosis and cardiomyopathy.
Xia P; Liu Y; Chen J; Coates S; Liu DX; Cheng Z
J Biol Chem; 2018 Dec; 293(51):19672-19685. PubMed ID: 30361442
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of CDK7 mitigates doxorubicin cardiotoxicity and enhances anticancer efficacy.
Chen J; Wei J; Xia P; Liu Y; Belew MD; Toohill R; Wu BJ; Cheng Z
Cardiovasc Res; 2024 Apr; ():. PubMed ID: 38646672
[TBL] [Abstract][Full Text] [Related]
5. Targeted expression of cyclin D2 ameliorates late stage anthracycline cardiotoxicity.
Zhu W; Reuter S; Field LJ
Cardiovasc Res; 2019 Apr; 115(5):960-965. PubMed ID: 30423020
[TBL] [Abstract][Full Text] [Related]
6. Focal adhesion kinase antagonizes doxorubicin cardiotoxicity via p21(Cip1.).
Cheng Z; DiMichele LA; Rojas M; Vaziri C; Mack CP; Taylor JM
J Mol Cell Cardiol; 2014 Feb; 67():1-11. PubMed ID: 24342076
[TBL] [Abstract][Full Text] [Related]
7. Loss of Rbl2 (Retinoblastoma-Like 2) Exacerbates Myocardial Ischemia/Reperfusion Injury.
Chen J; Xia P; Liu Y; Kogan C; Cheng Z
J Am Heart Assoc; 2022 Oct; 11(19):e024764. PubMed ID: 36129061
[TBL] [Abstract][Full Text] [Related]
8. Deubiquitinase OTUB1 regulates doxorubicin-induced cardiotoxicity via deubiquitinating c-MYC.
Xu F; Zang T; Chen H; Zhou C; Wang R; Yu Y; Shen L; Qian J; Ge J
Cell Signal; 2024 Jan; 113():110937. PubMed ID: 37871668
[TBL] [Abstract][Full Text] [Related]
9. PDE10A Inactivation Prevents Doxorubicin-Induced Cardiotoxicity and Tumor Growth.
Chen S; Chen J; Du W; Mickelsen DM; Shi H; Yu H; Kumar S; Yan C
Circ Res; 2023 Jul; 133(2):138-157. PubMed ID: 37232184
[TBL] [Abstract][Full Text] [Related]
10. VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection.
Räsänen M; Degerman J; Nissinen TA; Miinalainen I; Kerkelä R; Siltanen A; Backman JT; Mervaala E; Hulmi JJ; Kivelä R; Alitalo K
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13144-13149. PubMed ID: 27799559
[TBL] [Abstract][Full Text] [Related]
11. P53 inhibition exacerbates late-stage anthracycline cardiotoxicity.
Zhu W; Zhang W; Shou W; Field LJ
Cardiovasc Res; 2014 Jul; 103(1):81-9. PubMed ID: 24812279
[TBL] [Abstract][Full Text] [Related]
12. Gasdermin D mediates doxorubicin-induced cardiomyocyte pyroptosis and cardiotoxicity via directly binding to doxorubicin and changes in mitochondrial damage.
Ye B; Shi X; Xu J; Dai S; Xu J; Fan X; Han B; Han J
Transl Res; 2022 Oct; 248():36-50. PubMed ID: 35545198
[TBL] [Abstract][Full Text] [Related]
13. Machine Learning Identifies Clinical and Genetic Factors Associated With Anthracycline Cardiotoxicity in Pediatric Cancer Survivors.
Chaix MA; Parmar N; Kinnear C; Lafreniere-Roula M; Akinrinade O; Yao R; Miron A; Lam E; Meng G; Christie A; Manickaraj AK; Marjerrison S; Dillenburg R; Bassal M; Lougheed J; Zelcer S; Rosenberg H; Hodgson D; Sender L; Kantor P; Manlhiot C; Ellis J; Mertens L; Nathan PC; Mital S
JACC CardioOncol; 2020 Dec; 2(5):690-706. PubMed ID: 34396283
[TBL] [Abstract][Full Text] [Related]
14. Isorhapontigenin protects against doxorubicin-induced cardiotoxicity
Wang P; Wang M; Hu Y; Chen J; Cao Y; Liu C; Wu Z; Shen J; Lu J; Liu P
Acta Pharm Sin B; 2021 Mar; 11(3):680-693. PubMed ID: 33777675
[TBL] [Abstract][Full Text] [Related]
15. Anthracycline cardiotoxicity is exacerbated by global p38β genetic ablation in a sexually dimorphic manner but unaltered by cardiomyocyte-specific p38α loss.
George SA; Kiss A; Trampel KA; Obaid SN; Tang L; Efimov IR; Efimova T
Am J Physiol Heart Circ Physiol; 2023 Nov; 325(5):H983-H997. PubMed ID: 37624097
[TBL] [Abstract][Full Text] [Related]
16. Adiponectin agonist ADP355 ameliorates doxorubicin-induced cardiotoxicity by decreasing cardiomyocyte apoptosis and oxidative stress.
Zhao D; Xue C; Li J; Feng K; Zeng P; Chen Y; Duan Y; Zhang S; Li X; Han J; Yang X
Biochem Biophys Res Commun; 2020 Dec; 533(3):304-312. PubMed ID: 32958254
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin induces cardiotoxicity in a pluripotent stem cell model of aggressive B cell lymphoma cancer patients.
Haupt LP; Rebs S; Maurer W; Hübscher D; Tiburcy M; Pabel S; Maus A; Köhne S; Tappu R; Haas J; Li Y; Sasse A; Santos CCX; Dressel R; Wojnowski L; Bunt G; Möbius W; Shah AM; Meder B; Wollnik B; Sossalla S; Hasenfuss G; Streckfuss-Bömeke K
Basic Res Cardiol; 2022 Mar; 117(1):13. PubMed ID: 35260914
[TBL] [Abstract][Full Text] [Related]
18. Protease-activated receptor 1 activation enhances doxorubicin-induced cardiotoxicity.
Antoniak S; Tatsumi K; Schmedes CM; Grover SP; Pawlinski R; Mackman N
J Mol Cell Cardiol; 2018 Sep; 122():80-87. PubMed ID: 30098988
[TBL] [Abstract][Full Text] [Related]
19. Proteasomal Degradation of TRAF2 Mediates Mitochondrial Dysfunction in Doxorubicin-Cardiomyopathy.
Dhingra R; Rabinovich-Nikitin I; Rothman S; Guberman M; Gang H; Margulets V; Jassal DS; Alagarsamy KN; Dhingra S; Valenzuela Ripoll C; Billia F; Diwan A; Javaheri A; Kirshenbaum LA
Circulation; 2022 Sep; 146(12):934-954. PubMed ID: 35983756
[TBL] [Abstract][Full Text] [Related]
20. Signalling mechanisms underlying doxorubicin and Nox2 NADPH oxidase-induced cardiomyopathy: involvement of mitofusin-2.
McLaughlin D; Zhao Y; O'Neill KM; Edgar KS; Dunne PD; Kearney AM; Grieve DJ; McDermott BJ
Br J Pharmacol; 2017 Nov; 174(21):3677-3695. PubMed ID: 28261787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
